Grid Therapeutics Initiates a Phase 2 Investigator-Sponsored Trial of GT103 in Combination with Merck’s Pembrolizumab in Patients with Advanced NSCLC Read more
Grid Therapeutics Selected by the NCI’s NExT Program to Complete the IND Enabling Nonclinical Work for GT103